Overview of Анальгин

Quick Facts

Property	Description
Active Ingredient	Metamizole Sodium (Dipyrone)
Pharmacological Class	Analgesic, Antipyretic, Spasmolytic
Origin	Synthetic Pyrazolone Derivative
Primary Forms	Tablet, Solution for Injection, Suppositories
General Purpose	Pain Relief and Fever Reduction

What is Анальгин and its Chemical Composition?

Анальгин is the common trade name for the pharmaceutical substance Metamizole Sodium, which is internationally recognized as Dipyrone. This compound is a synthetic pyrazolone derivative and functions as a pro-drug that is rapidly metabolized in the body into the therapeutically active component, 4-methyl-amino-antipyrine (MAA). This compound is clinically recognized for its potent effects compared to some non-opioid alternatives. As a monodrug, its composition is strictly based on the active ingredient combined with solid excipients for formulations like the tablet and suppositories, or dissolved in an aqueous base/vehicle for injectable and oral liquid forms.

Pharmacological Classification and General Purpose

Metamizole Sodium is categorized by the World Health Organization's ATC system as an analgesic and antipyretic agent. Its core therapeutic purpose is the management of pain and the reduction of high fever. A differentiating factor is its potent spasmolytic property, meaning it helps to relax smooth muscle tissue, which is a key advantage when managing pain associated with spasmodic conditions. Metamizole provides significant non-opioid pain relief, acting effectively in acute pain scenarios. This medicine offers powerful relief from various types of pain without possessing the dependence risk of narcotics.

Physical Forms and Pharmaceutical Types

The drug entity Metamizole Sodium is manufactured in several versatile dosage form types, providing flexibility in the route of administration. These forms include the solid oral tablet and suppositories for rectal delivery. Liquid forms, such as the injectable solution packaged in ampoules and the oral liquid preparation, are also standard. The broad availability across oral, injectable, and rectal pathways is a differentiating feature that ensures the medication can be administered even in acute, non-oral situations, maximizing its utility in various clinical and home settings.

What side effects are possible with Анальгин?

Possible Side Effects and Safety Information

The regulatory safety profile of Metamizole Sodium (Анальгин) is characterized by the potential for rare, serious adverse events that primarily affect the blood and immune systems, as documented in official government labeling. Adverse reactions are classified by their frequency and grouped into System-Organ Classes (SOCs).

Serious and Clinically Significant Reactions

The most critical documented safety concern is agranulocytosis, a severe blood disorder that is not related to the administered dose and can manifest at any time during treatment or shortly after cessation. Other serious adverse reactions include potentially fatal anaphylactic shock and severe skin conditions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Acute liver injury or failure has also been reported in regulatory documents.

Frequency Classification	Associated Safety Domain (Examples)
Rare	Blood and lymphatic system disorders (e.g., Agranulocytosis)
Uncommon	Immune system disorders, Skin disorders (e.g., Urticaria)
Common	Vascular disorders (e.g., Hypotension, especially with rapid IV administration)

Population-Specific Constraints

The medication is contraindicated during the third trimester of pregnancy due to risks to the fetal circulatory and renal systems. Use is also not recommended during breastfeeding. Administration is constrained for infants below 3 months of age or 5 kg body weight. Individuals with pre-existing conditions like impaired bone marrow function or a history of Metamizole-induced agranulocytosis are also subject to contraindication. Severe hypotensive reactions are officially noted as more likely following a rapid rate of injection.

Overdose and Emergency Response

Overdose and When to Seek Urgent Medical Help

Analgin (Metamizole) is associated with a risk of a life-threatening, non-dose-related condition called agranulocytosis. This condition is characterized by a severe drop in certain white blood cells and can lead to fatal infections, which necessitates immediate action.

Seek Immediate Medical Attention if:

You develop signs of agranulocytosis at any time during or shortly after treatment. Symptoms typically include a new fever, chills, sore throat, or painful sores on the mouth, nose, throat, or genital/anal regions (mucosal surfaces). If these occur, the medicine must be stopped immediately.
You experience symptoms of anaphylactic shock or severe allergy, such as a sudden drop in blood pressure, swelling of the face or throat, or difficulty breathing.

Acute Overdose Manifestations

Symptoms following a very high single dose (e.g., above 7.5 grams) may involve the gastrointestinal system, including nausea, vomiting, and abdominal pain. Overdose can also affect the central nervous system, and in rare, severe cases, may lead to renal dysfunction or severe low blood pressure (hypotension).

Emergency Actions (as per official guidance):

In the event of an acute, high-dose ingestion, emergency treatment is supportive. It may include steps to limit drug absorption, such as administering activated charcoal, and measures to accelerate elimination, such as haemodialysis, depending on the severity and time since ingestion.

Therapeutic Uses of Анальгин

What Analgin Treats: Main Uses and Benefits

Metamizole-containing medicines are relevant for treating moderate to severe pain and fever that may be difficult to manage with standard treatment options. This is consistent with its use in situations involving symptomatic discomfort. The medication is commonly used to help manage pain associated with musculoskeletal disorders, certain headaches, dental procedures, and post-traumatic discomfort, as well as the intense, cramping discomfort of renal, biliary, and intestinal colic.

“The symptomatic relief provided helps ease the overall symptom load during acute symptomatic episodes.”

Quick Fact: Relief for Spasm and Fever

Domain	Symptom Management	Benefit Provided
Pain	Moderate to severe pain, post-traumatic and dental discomfort	Helps maintain a sense of stability when symptoms are more noticeable.
Spasm	Visceral pain caused by smooth muscle contractions (colic)	Offers supportive relief when symptoms interfere with routine activities.
Fever	High-grade, persistent elevated body temperature (pyrexia)	Contributes to improved comfort during periods of heightened symptoms.

The drug is applied in clinical settings that involve acute or unstable symptom patterns, offering supportive assistance in easing the intense symptoms and contributing to improved comfort during symptomatic periods. It is relevant when symptoms create noticeable physiological strain and short-term symptomatic assistance is needed.

Regulatory References

European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

The eligibility for using Анальгин (Metamizole Sodium) is strictly defined by regulatory documents, emphasizing patient history, physiological status, and age.

Populations for Whom Use is Contraindicated

Contraindications prohibit the use of the medicine in certain populations due to high risk:

Patients with a prior history of agranulocytosis induced by metamizole or other pyrazolone compounds.
Patients with impaired bone marrow function or established diseases of the hematopoietic system.
Individuals with genetic glucose-6-phosphate-dehydrogenase (G6PD) deficiency or acute intermittent hepatic porphyria.
The third trimester of pregnancy and infants below 3 months of age or weighing less than 5 kg.

Age and Physiological Restrictions

Eligibility Classification	Population Group	Regulatory Status
Age-Related	Adults and Adolescents (15+ years)	Approved for use under standard conditions.
Pediatric	Children (3 months and older)	Permitted, generally requires weight-based dosing.
Geriatric	Older Adults and Debilitated Patients	Restricted use; dose reduction is formally required.
Organ Function	Renal or Hepatic Impairment	Restricted use; multiple high doses must be avoided.

Pregnancy and Lactation Status

Use is contraindicated during the third trimester of pregnancy due to documented fetal risks. For breastfeeding, repeated use is not recommended; after a single administration, breast milk must be discarded for a 48-hour period, as metabolites pass into the milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metamizole (Analgin) is documented to interact with various medicines primarily through pharmacokinetic (affecting drug concentrations) and pharmacodynamic (affecting drug activity) mechanisms, as stated in official regulatory information.

Key interacting drug classes and specific medicines are listed below:

Interacting Product Category	Official Regulatory Statement
Immunosuppressants (e.g., Cyclosporine)	Co-administration can reduce the concentration of Cyclosporine, necessitating the monitoring of plasma levels and potential dosage adjustment of Cyclosporine.
Acetylsalicylic Acid (Aspirin)	Metamizole may reduce the antiplatelet effect of low-dose aspirin used for cardiovascular protection; a timing separation between doses is recommended to preserve aspirin's efficacy.
Antihypertensives	Metamizole may reduce the effects of specific antihypertensive agents (e.g., Captopril, Triamterene) and Lithium.
Phenothiazines (e.g., Chlorpromazine)	Concurrent use can lead to the risk of severe hypothermia.
CYP Substrates/Inducers	Metamizole is an enzyme inducer and inhibitor, which can alter the plasma concentrations of many co-administered medicines that are substrates for CYP3A4, CYP2B6, CYP2C19, and CYP1A2.

The regulatory profile identifies that Metamizole can lower the exposure of certain medicines due to enzyme induction or compete for binding sites, which may decrease the desired clinical action of the co-administered drug. The interaction with other bone marrow-suppressing agents is noted as potentially masking the early signs of agranulocytosis.

Mechanism of Action

How Анальгин Works

Анальгин (Metamizole) exerts its action through three principal mechanistic domains. Primarily, it functions as an inhibitor of Cyclooxygenase (COX) enzyme activity, particularly within the central nervous system (CNS), which leads to a substantial suppression of prostaglandin synthesis. This core action suppresses the central propagation of nociceptive signals and modifies the hypothalamic set point for thermoregulation, leading to a modification in signal transmission and thermoregulatory set-point activity.

Secondarily, the drug is involved in the modulation of specific receptors in the endogenous opioid and cannabinoid systems within the CNS. This interaction promotes activity within the body's internal analgesic pathways, contributing to the modulation of descending pain pathway dynamics.

Finally, a third distinct mechanism involves direct interference with calcium ion mobilization within the smooth muscle cells of internal organs. This action alters the calcium flux dynamics, resulting in a reduction in smooth muscle contractility.

Dosage and Administration Information

Instruction Map: How to use Анальгин — Official Administration Guidelines

Administration Scope

Category	Official Instructions (Strictly Regulatory)
Route of administration	Administration is officially approved via the Oral (tablet, solution/drops), Intravenous (IV), Intramuscular (IM), and Rectal (suppositories) routes.
Dosing schedule (Adults 15 years)	The maximum single oral dose is 1,000 mg. The maximum daily dose is 4,000 mg for oral use and 5,000 mg for parenteral use. Official instructions specify the use of the lowest effective dose.
Timing in relation to meals	No specific condition regarding meals is consistently documented.
Age-group administration rules	Pediatric: Dosing is calculated based on body weight, generally 8-16 mg/kg as a single dose. Infants (under 1 year): The injectable form must be administered by the intramuscular route only.
Special procedural conditions	Intravenous administration must be performed very slowly to mitigate potential issues. Dose reduction is necessary for older adults and individuals with reduced metabolic clearance. The overall course is intended for short-term use.

Instruction Classifications (High-Level)

Classification	Description
Administration method type	Oral, Parenteral (IV, IM), and Rectal.
Frequency pattern	Intermittent, with single doses taken up to 4 times daily at 6-8 hour intervals.
Regulatory basis	Governed by established national health agency and product characteristic guidelines.
Use-context constraints	Intended for short-term use only, with mandated dosing intervals.

Resulting Procedural Structure

Official step sequence:

Dose Selection: Use the lowest dose that provides symptomatic relief, while not exceeding the single-dose or daily maximums.
Interval Maintenance: Maintain a minimum separation of 6 to 8 hours between administrations.
Parenteral Technique: Administer the IV solution very slowly and, if required by the formulation, only via the IM route for certain pediatric groups.

Connection to the overall use protocol (2–4 sentences): The official instructions establish a standardized protocol centered on flexible administration routes, strict daily dosing limits, and mandatory time spacing. This framework dictates the standardized approach to delivering the medicine, ensuring that administration is governed by defined boundaries concerning frequency, total quantity, and necessary procedural techniques.

Recent Clinical Evidence

Clinical Efficacy and Pain Management

Recent clinical research, including systematic reviews and meta-analyses, continues to examine the efficacy and safety profile of Metamizole (often sold as Analgin or Dipyrone) in pain and fever management. Studies indicate that a single oral dose of 500 mg of Metamizole is associated with acceptable pain relief for a significant proportion of people experiencing moderate or severe acute pain, such as postoperative pain.

Its effectiveness has been compared to that of other non-opioid analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) for various acute conditions, including post-surgical discomfort and colic pain. Research suggests that Metamizole may provide relief comparable to, or in some acute settings, greater than, certain conventional treatments.

Safety and Regulatory Considerations

The most serious, though rare, adverse effect associated with Metamizole is agranulocytosis—a sharp reduction in white blood cells that increases the risk of serious infection. Incidence estimates for this rare event vary significantly across regions, from less than one case per million treatments up to higher rates in some populations, leading to varying regulatory status globally; the drug is restricted or banned in several countries (e.g., the United States, Japan, and the UK) but widely used in others (e.g., Germany, Russia, Spain).

Ongoing pharmaco-epidemiological studies and safety reviews, such as those conducted by the European Medicines Agency (EMA), continue to assess the benefit-risk ratio. These reviews emphasize the need for caution and patient monitoring for symptoms indicative of agranulocytosis (like fever or sore throat), which can occur at any time during treatment.

Frequently Asked Questions (FAQ)

Common questions about Анальгин (FAQ)

Q: How does the general effect of Анальгин compare to common pain relievers like paracetamol (acetaminophen)?

Official documents classify Metamizole as a substance for both pain and fever relief. Research has examined its effectiveness compared to other non-opioid analgesics. Studies suggest Metamizole can provide relief comparable to certain conventional non-opioid treatments in acute pain scenarios.

Q: What are the most frequently reported common side effects of taking Анальгин?

According to official product safety information, commonly reported, non-serious side effects may include symptoms like dizziness, nausea, and vomiting. Some people may also experience abdominal pain or dyspepsia, which is an uncomfortable feeling of indigestion. The full section on possible side effects contains more comprehensive information.

Q: What are the descriptive signs of a possible serious allergic reaction to Анальгин?

Serious allergic reactions, including anaphylaxis, are listed as a risk in regulatory warnings. These serious reactions are described as potentially involving swelling of the throat (laryngeal swelling), difficulty breathing (bronchospasm), or severe skin changes. A sudden, rapid drop in blood pressure may also occur in these serious cases.

Q: What types of headache pain is Анальгин officially used to manage?

Official indications include severe acute pain, such as pain following surgery and pain associated with colic. In clinical contexts, it has been used for pain related to migraine.

Q: Is Анальгин classified as an NSAID (non-steroidal anti-inflammatory drug) in regulatory documents?

Metamizole is officially categorized as a pyrazolone derivative, which is a different class of medicine. It is not classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) but does share some similar mechanisms, such as pain and fever relief. Additionally, it has a recognized spasmolytic (muscle-relaxing) action.

Q: Does Анальгин contain codeine, opiates, or any narcotic substances?

No. According to pharmacological classification, Metamizole, the active substance in Анальгин, is a non-opioid medicine. It is classified as an analgesic and antipyretic agent and does not contain opiates or narcotic substances.

Q: Why is the name Analgin used in some regions and Metamizole in others?

The differences in drug names are due to regional trade name registrations and historical practices in various regulatory markets. 'Анальгин' is a widely recognized brand name used in several areas for the active substance, which is internationally recognized as Metamizole Sodium or Dipyrone.

Q: What is the general difference between the tablet form and the suppository form of Анальгин?

The main difference lies in the route of administration: the tablet is taken orally, while the suppository is administered rectally. The official guidance notes that suppositories are generally a pathway for administration when swallowing is difficult or when oral intake is undesirable, such as during episodes of vomiting.

Q: How quickly can a person typically expect Анальгин to begin working for pain?

Official pharmacokinetic data indicates that the pain-relieving action typically begins within 20 to 40 minutes after the medicine is taken. The maximum effect of the medicine is generally reached within two hours of administration.

Q: What is the general duration of pain relief that Анальгин provides?

While the duration of relief can vary by individual, regulatory dosing guidelines provide a framework for the medicine’s activity. Official instructions require maintaining a minimum interval of 6 to 8 hours between single administrations.

Q: Can Анальгин cause stomach issues like irritation or bleeding?

Yes. Regulatory safety information indicates that Metamizole can potentially cause gastrointestinal side effects. These reactions can include stomach upset (dyspepsia) and may be associated with a risk of upper gastrointestinal bleeding.

Q: What is the official information regarding the combination of Анальгин and alcohol consumption?

Official guidance highlights the need for caution regarding alcohol consumption while using this medicine. Alcohol consumption may potentially increase the risk of certain side effects, especially those affecting the gastrointestinal tract.

Q: Does Анальгин have any known sedative or drowsy effects?

Dizziness is listed as a potential side effect in the official product information. Regulatory warnings indicate that due to the potential for dizziness and impaired concentration, operating machinery or driving should be avoided unless the individual is certain they are fully alert.

Q: Can using Анальгин potentially affect the results of standard laboratory blood tests?

Yes. Official labeling indicates that Metamizole may interfere with the accuracy of results from certain laboratory blood tests. This can affect the measurement of serum levels for substances such as creatinine, triglycerides, HDL cholesterol, and uric acid.

Q: What does research evidence indicate about the effectiveness of Анальгин for muscle pain?

Official documents recognize that Metamizole has a distinct spasmolytic (smooth muscle-relaxing) property. While specific research often centers on pain associated with internal organs (like colic), this spasmolytic effect is generally beneficial for pain linked to muscle spasms.

Q: What is the typical half-life or how long does Анальгин stay in the system?

Based on pharmacokinetic data, the elimination half-life of the drug's primary active substance is approximately six hours. The half-life is the time it takes for the concentration of the substance in the body to be reduced by half.

Q: What does the patient information leaflet state about Анальгин use for people with a history of asthma?

The patient information leaflet advises caution for individuals with a history of asthma, nasal polyps, or chronic hives (urticaria). The leaflet advises that these patients should ensure their healthcare provider is aware of their condition prior to the use of Metamizole.

Q: Can Анальгин affect a person's ability to drive or safely operate machinery?

Official warning information exists regarding this potential effect. Since the medicine may cause dizziness and impair concentration, regulatory information indicates that driving or operating complex machinery should be avoided unless the individual is certain they are fully alert and free of side effects.

Q: What is the official information regarding the signs of a potential overdose with Анальгин?

Official overdose information describes symptoms that can include hypothermia (low body temperature) and low blood pressure (hypotension). Other reported signs are ringing in the ears (tinnitus), drowsiness, delirium, seizures, and potentially severe organ damage to the liver or kidneys.

Q: What is the potential interaction described between Анальгин and anti-clotting medications (anticoagulants)?

Official regulatory documents warn that Metamizole may interfere with the antiplatelet effect of low-dose aspirin used to protect the heart and circulation. For this reason, a careful timing separation between doses may be advised. Individuals using other anti-clotting medications should be monitored for potential interactions.

Q: Is Анальгин listed on the World Health Organization's essential medicines list?

No, Metamizole (often sold as Анальгин) is not included on the World Health Organization's Essential Medicines List. This list identifies medicines considered high priority for a basic health care system globally.

How should Анальгин be stored and disposed of?

How to Store and Dispose of Анальгин (Metamizole Sodium)

Official regulatory guidelines define specific conditions for storing and disposing of Analgin to maintain its stability and protect the environment.

Storage Requirements	Disposal Requirements
Store at controlled room temperature, generally not exceeding 25 C.	Do not release into drains, sewers, or the environment due to water hazard classification.
Do not freeze. Keep the product in the original packaging to protect it from light and moisture.	Dispose of unused or expired product through an authorized pharmaceutical waste collection program or plant.
Keep out of the reach of children.

These constraints ensure the medicine's integrity throughout its shelf life and adhere to environmental protection standards for pharmaceutical waste.

Анальгин